Long-term follow-up of autoantibody profiles in Black female lupus patients and clinical comparison with Caucasian and Asian patients

British Journal of Rheumatology

Volumn 36, Issue 2, 1997, Pages 229-233

  Isenberg, D A ^a,c   Garton, M ^a   Reichlin, M W ^b   Reichlin, M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c Arthur Stanley House   (United Kingdom)

Author keywords

Autoantibodies; SLE

Indexed keywords

ANTIBODY; AUTOANTIBODY; DNA ANTIBODY;

ADULT; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; NEGRO; ONSET AGE; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0347246521     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.2.229     Document Type: Article

References (27)

1. Isenberg DA, Horsfall AC. Systemic lupus erythematosus: adult onset disease. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology. Oxford: 733-55.
2. Isenberg DA, Ehrenstein M, Longhurst C, Kalsi J. The origin, sequence, structure and consequences of developing anti-DNA antibodies - a human perspective. Arthritis Rheum 1994;37:169-80.
3. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in SLE and non-SLE disorders. Ann Intern Med 1990;112:682-98.
4. Asherson RA, Khamashta MA, Ordi-Ros J et al. The 'primary' anti-phospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
5. Emlen W, Pisetsky DS, Taylor RP. Antibodies to DNA. A perspective. Arthritis Rheum 1986;29:1417-26.
6. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serological features. Am J Med 1979;66:210-5.
7. Liang M, Sacher SA, Roberts WN, Esdaile JM. Measurement of SLE activity in clinical research. Arthritis Rheum 1988;31:817-25.
8. Worrall J, Snaith ML, Batchelor R, Isenberg DA. SLE - a rheumatological view. Q J Med 1990;275:319-30.
9. McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black-female patients with lupus nephritis. Arthritis Rheum 1993;36:1560-5.
10. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith M et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
11. Morrow WJW, Isenberg DA, Todd-Pokropek A, Snaith ML. Laboratory measurements useful in the management of systemic lupus erythematosus. Q J Med 1982;51:125-38.
12. Gladman D, Goldsmith U, Urowitz M, Bacon P, Bombardier C, Isenberg DA et al. Sensitivity to change of 3 lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
13. Isenberg DA, Williams W, Le Page S, Swana G, Feldman R, Addison I et al. A comparison of autoantibodies and common DNA idiotypes in SLE patients and their spouses. Br J Rheumatol 1988;27:431-5.
14. Kausman D, Isenberg DA. Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol 1995;34:361-4.
15. Wasicek CA, Reichlin M. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J Clin Invest 1982;69:835-43.
16. Maddison PJ, Isenberg DA, Goulding N, Leddy J, Skinner RP. Anti La (SSB) identifies a distinctive subgroup of SLE. Br J Rheumatol 1988;17:27-31.
17. Joseph A, Anaya JM, Sandifer M, Scopelitis E, Wilson W, Espinoza LR. Absence of a distinctive autoantibody profile in black women with lupus nephritis. Arthritis Rheum 1994;8:1261-4.
18. McCarty GA, Harley JB, Reichlin M. Reply to letter by Joseph J, Anaya JM, Sandifer M, Scopelitis E, Wilson W, Espinoza LR. Arthritis Rheum 1994;37:1262-3.
19. Arnett FC Jr. The genetic basis of lupus erythematosus. In: Wallace DJ, Kahn BH, eds. Dubois' lupus erythematosus, 4th edn. Philadelphia: Lea & Febiger, 1993:13-36.
20. Wallace DJ. The clinical presentation of SLE. In: Wallace DJ, Kahn BH, eds. Dubois' lupus erythematosus, 4th edn. Philadelphia: Lea & Febiger, 1993:317-21.
21. Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989;32:1226-32.
22. Tucker LB, Menon S, Schaller J, Isenberg DA. Adult and childhood onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br J Rheumatol 1995;34:866-72.
23. Studenski S, Allen NB, Caldwell DS, Rice JR, Polisson RP. Survival in systemic lupus erythematosus. Arthritis Rheum 1987;30:1326-31.
24. Yamagata H, Harley JB, Reichlin M. Molecular properties of the Ro/SSA antigen and ELISA for quantitation of antibody. J Clin Invest 1984;74:625-33.
25. Harley JB, Yamagata H, Reichlin M. Anti-La/SSB antibody is present in some normal sera and is coincident with anti-Ro/SSA precipitins in systemic lupus erythematosus. J Rheumatol 1984;11:309-14.
26. Reichlin M. Measurement of antibodies to Sm and nRNP by ELISA: Clinical and serological correlations. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier Science Publishers B.V., 1987:85-96.
27. Hulsey M, Goldstein R, Scully L, Surbeck W, Reichlin M. Anti-ribosomal P antibodies in systemic lupus erythematosus. A case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995;74:252-6.